Irinotecan (and liposomal irinotecan)

Medicare

Part B (clinician-administered)

Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Generic irinotecan; liposomal irinotecan (Onivyde) is a branded Part B drug that plans may review.

Commercial insurance

covered on label

Multi-source generic; covered under the medical benefit without prior authorisation in most plans, as part of standard regimens. Onivyde usually requires prior authorisation.

Assistance programmes

• Ipsen Cares
• PAN Foundation — Disease-specific co-pay and premium funds; open and closed funds change monthly.
• HealthWell Foundation
• CancerCare Co-Payment Assistance Foundation
• Patient Advocate Foundation Co-Pay Relief

Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.

Appraised for

Irinotecan, oxaliplatin and raltitrexed for advanced colorectal cancer

Notes

Generic; funded routinely. Liposomal irinotecan (Onivyde) with 5-FU for pancreatic cancer after gemcitabine was appraised in TA440 (2017).

NHS England

Routinely funded for the appraised indication (or via managed access)

Sources: NICE TA93 · SMC advice: irinotecan. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.